ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Business deals

Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

U.S. drugmaker sees promise in target company's technologies

U.S. drugmaker Moderna will acquire Japan's OriCiro Genomics.   © Reuters

(Reuters) -- Moderna on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's messenger RNA (mRNA) manufacturing capabilities.

The Japanese company is working on the development and commercialization of cell-free synthesis and amplification of a type of DNA molecule for use in mRNA manufacturing.

OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.

Moderna's mRNA technology has been used in developing COVID-19 vaccines.

Last month, an experimental cancer vaccine from Moderna based on the technology was shown to work against melanoma, a type of skin cancer.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more